Dr. Kammula is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5150 Centre Ave
Ste 414
Pittsburgh, PA 15232Phone+1 412-623-4861Fax+1 412-692-2520
Summary
- Udai S. Kammula, MD, FACS, is an associate professor and director of the Solid Tumor Cell Therapy Program at UPMC Hillman Cancer Center, and surgical oncologist in the Department of Gastrointestinal Surgical Oncology. His research and clinical expertise includes cancer immunology, adoptive T cell transfer, gene therapy, and tumor-infiltrating lymphocytes.
Board-certified in surgery, Dr. Kammula received his medical degree from the University of Maryland School of Medicine in Baltimore. He completed his general surgery residency at University of Chicago Medical Center, IL, and his surgical oncology and immunotherapy clinical and research fellowship at the National Cancer Institute in Bethesda, MD. He also completed a surgical oncology fellowship at Memorial Sloan Kettering Cancer Center in New York.
Education & Training
- Memorial Sloan Kettering Cancer CenterFellowship, Complex General Surgical Oncology, 2002 - 2004
- University of ChicagoResidency, Surgery, 1994 - 2002
- University of Maryland School of MedicineClass of 1994
Certifications & Licensure
- PA State Medical License 2017 - 2024
- NY State Medical License 2002 - 2017
- MD State Medical License Active through 2014
- IL State Medical License 1996 - 2002
- American Board of Surgery Surgery
Awards, Honors, & Recognition
- Fellow American College of Surgeons
Clinical Trials
- Chemotherapy Followed by gp100 Lymphocytes and Aldesleukin to Treat Melanoma Start of enrollment: 2008 Apr 01
- Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma Start of enrollment: 2013 Mar 01
- Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma Start of enrollment: 2018 May 14
- Join now to see all
Publications & Presentations
PubMed
- 3 citationsUveal melanoma immunogenomics predict immunotherapy resistance and susceptibility.Shravan Leonard-Murali, Chetana Bhaskarla, Ghanshyam S Yadav, Sudeep K Maurya, Chenna R Galiveti
Nature Communications. 2024-04-16 - 5 citationsGenome-wide gain-of-function screening characterized lncRNA regulators for tumor immune response.Yifei Wang, Yueshan Zhao, Weiwei Guo, Ghanshyam Singh Yadav, Chetana Bhaskarla
Science Advances. 2022-12-09 - 6 citationsIn Vivo Priming of Peritoneal Tumor-Reactive Lymphocytes With a Potent Oncolytic Virus for Adoptive Cell TherapyEsther Giehl, Hiromichi Kosaka, Zuqiang Liu, Mathilde Feist, Udai S. Kammula
Frontiers in Immunology. 2021-02-18
Press Mentions
- Immunogenomics Is on the Way UpAugust 12th, 2024
- Beckwith Institute Awards Research GrantsJune 30th, 2021
- Why Everyone Should Care About Uveal MelanomaDecember 7th, 2018
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: